Please use this identifier to cite or link to this item:
|Title:||Inter-firm Collaboration in New Product Development in Chinese Pharmaceutical Companies|
|Keywords:||Inter-firm collaboration;New product development;Chinese pharmaceutical companies;Resource-based view;Institution-based view;Transaction cost economies|
|Publisher:||SPRINGER VERLAG (GERMANY)|
|Citation:||Asia Pacific Journal of Management, 2016, 33 (1), pp. 165 - 193|
|Abstract:||High-tech firms increasingly rely on inter-firm collaboration (IFC) in new product development (NPD). While there is a growing research interest in exploring the economic rationale of IFC through the transaction cost economics (TCE) and the resource synergy of IFC through the resource-based view of the firm (RBV), little attention has been given to the institution-based view (IBV) that also has important implications for firms’ choice of IFC. In particular, how national institutional environment affects IFC in the NPD process remains under-researched. This study aims to contribute to the literature by extending our understanding of the role of IFC in firms’ NPD process, taking into account transactional, resource, and institutional factors. Based on a case study of two firms: a state-owned and a private pharmaceutical firm in China, our research identifies three key forms of IFC, which are dynamic at different stages of NPD and contingent upon an array of institutional, resource, and transactional rationales underpinning firms’ choice of different forms of IFC. Our study is the first one that investigates the role of IFC in the NPD process bringing together the IBV, RBV, and TCE perspectives.|
|Appears in Collections:||Brunel Business School Research Papers|
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.